Become an Industry Collaborator

The Industry Collaboration Team (ICT) is an annual GOG Foundation membership program designed and developed to foster and facilitate a two-way communication channel between Industry and the GOG Foundation. We strive to build a strong partnership with Industry in order to serve as their research and collaboration partner, paving the way for advancement in the field of gynecologic oncology.

Member Benefits and Opportunities

  • Provides the opportunity to establish a two-way communication channel between industry and the GOG Foundation
  • For a more rapid accumulation of information for pooling knowledge by multidisciplinary organizations and industry
  • Fosters interaction between leaders in oncology and industry
  • An opportunity to extend information about new and improving technologies, equipment, products, and services to
    professionals working in gynecologic cancer research
Member Benefits Preferred $25,000 Standard $6,000

Foundation Support:

  • Support Clinical Trial Research
  • Promote awareness through research
  • New Investigator mentoring
Yes Yes

Meeting Registration Badge Fee:

Representatives attending will receive complimentary badge fee along with relevant CME certificate(s)

Yes Yes


Representatives attending will receive complimentary badge fee and CME certificate (Pre-registration only)

  • Additional representatives to register $125/each ($150/each On-site)
Yes No
Additional Benefits
Your company profile on Yes Yes
A direct link to your website Yes Yes
Recognition on meeting signs Yes Yes

Advisory Board Meeting Discount

Preferred members will receive a 20% discount to host an advisory Board meeting during NRG Oncology Semiannual meetings. GOG Foundation will act as your meeting planner and coordinate the event for up to 10 advisors for an additional fee (contact us for a detailed brochure). Please contact us to inquire about Advisory Board meetings held outside of the NRG Oncology Semiannual
meeting at (410) 721-7126 or via email at or

Yes No
(Standard Level members can request an upgraded membership for an Ad Board)

ICT Reception Invitation

An Invitation Only opportunity to join GOG Foundation Board of Directors and Committee Members at the ICT Reception.

Yes Four (4) Attendees Yes Two (2) Attendees

One–on-One Sessions:

Meet with up to five (5) GOG Partners Members to discuss a topic of your choice for one 40 minute session

Yes Yes



Company Website

To address healthcare challenges across the world, we unite a biotech spirit with the strength of a successful pharmaceutical business. The result is a biopharmaceutical company combining science, passion, and expertise to improve health and healthcare in new ways. Making a remarkable impact in people’s lives is more than our promise. It’s our purpose.


Company Website

Agenus is an immuno-oncology company driven by innovation. Our goal is to treat cancers with novel combinations utilizing our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines and adjuvants. In addition to a broad portfolio, we have an accomplished team of scientists, novel technology platforms and fully-integrated end-to-end capabilities from discovery to GMP manufacturing. With our remarkable combination of science and people, we believe that we are uniquely positioned to bring curative treatments to cancer patients.

Akeso, Inc.

Company Website

Akeso, Inc. is a public-listed biopharmaceutical company with an approved medicine and a rich pipeline of over 20 innovative investigational drugs for the treatment of major diseases such as cancer and autoimmune conditions. For oncology, the Company develops bispecific antibodies that target PD-1/CTLA-4 and PD-1/VEGF-A as well as antibodies against CD47, CD73, VEGFR-2 and TIGIT. Our vision is to become a global leader in developing, manufacturing and commercializing safer, more effective and more affordable therapeutic antibodies for patients worldwide.


Company Website

Bristol-Myers Squibb

Company Website

Bristol-Myers Squibb is the world leader in providing life-saving and life-extending therapies for people with cancer. All of the company’s considerable resources and expertise in oncology are marshaled toward the single goal of providing safer and more effective anticancer medicines. The mission of Bristol-Myers Squibb Oncology is to extend and enhance the lives of people living with cancer.


Company Website

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For more information on Celsion, visit

Clovis Oncology

Company Website

Clovis is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our development programs are targeted at specific subsets of cancer, combining personalized medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.


Company Website

Eisai Inc.

Company Website

Eisai Inc. is a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases).

Eli Lilly and Company

Company Website

Eli Lilly and Company is a leading innovation-driven corporation and is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.

Lilly Oncology is committed to providing comprehensive healthcare solutions – answers that matter – for oncologists and cancer patients around the world through the discovery and development of breakthrough cancer medicines.

EMD Serono

Company Website

At EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, our scientific approach focuses on three platforms—immuno-oncology, DNA damage response, and oncogenic pathways. In our aim to deliver breakthrough cancer therapies, we complement our internal expertise and development programs with a foundation of scientific collaborations to improve trial designs, accelerate treatment development, and partner on exciting asset programs and integrated innovations. Through this approach, together with our emphasis on biology-driven research, we aim to deliver personalized treatment options that may potentially transform cancer care.

Genentech Bioncology

Company Website

Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Genentech manufactures and commercializes several major oncology drugs include Herceptin, Rituxan, Avastin and Tarceva.


Company Website

Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.


Company Website

We are a biotechnology company focused on the development and commercialization of novel personalized therapeutics to treat cancer.


Company Website

GSK is focused on maximizing patient survival through transformational medicines. GSK’s oncology pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.

ImmunoGen, Inc.

Company Website

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen’s highly potent cancer-cell killing agents specifically to tumor cells; the Company has also developed antibodies with anticancer activity of their own. The most advanced compound with ImmunoGen’s ADC technology is Roche’s Kadcyla®. Additional compounds are in clinical testing by ImmunoGen and through the Company’s partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at


Company Website

For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Today, Merck continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.

Mersana Therapeutics

Company Website


Company Website


Company Website

Palti’s initial research from his basement laboratory has evolved to become an international oncology company with more than 450 employees and operations in the U.S., Europe and Asia.

We launched Optune® – our Tumor Treating Fields delivery system for glioblastoma (GBM) – in the United States for the treatment of recurrent glioblastoma in 2011. In October 2015, we received U.S. Food and Drug Administration (FDA) approval to market and sell Optune for the treatment of adult patients with newly diagnosed GBM in combination with temozolomide. We actively market for that indication in the United States, Germany and Switzerland.

The science of Tumor Treating Fields has the potential to extend beyond GBM. We have five ongoing or completed phase 2 pilot trials for brain metastases, non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. We presented our phase 2 pilot data in pancreatic and ovarian cancers at our research and development day on Dec. 12, 2016. In 2016, we began our phase 3 pivotal trial in brain metastases originating from NSCLC. In 2017, we started our phase 3 pivotal trial in NSCLC. Internationally, more than 20 institutions are studying the effects of Tumor Treating Fields in cancer treatment.

Our company began with a patient-forward approach that continues to drive our mission today. With more than 15 years of research and many significant milestones, we have established ourselves as an innovator in oncology dedicated to improving the lives of cancer patients.


Company Website

Seagen Inc. is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of clinical and preclinical development. We are utilizing our expertise in targeted therapies to build a portfolio of proprietary antibody-drug conjugates and immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors. For more information, visit


Company Website

VBL Therapeutics

Company Website

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, VB-111, is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. VB-111 is conveniently administered as an IV infusion once every two months. The mechanism of VB-111 combines blockade of tumor vasculature with an anti-tumor immune response. This mechanism retains activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor. VB-111 is currently being studied in a Phase 3 pivotal trial for Platinum Resistant Ovarian Cancer.